Korea's First Homegrown Weight-Loss Drug EPPE Launches: Can It Break the Wegovy Mounjaro Duopoly Efpeglenatide Explained

Korea's First Homegrown Weight-Loss Drug 'EPPE' Arrives: Can It Break the Wegovy–Mounjaro Duopoly?

For the past few years, the idea of shedding pounds with a single weekly injection has gripped South Korea. Two imported drugs, Wegovy and Mounjaro, have effectively owned the domestic obesity market. Now, for the first time, a weight-loss drug developed entirely with Korean technology is stepping onto the stage. Hanmi Pharmaceutical has finalized the brand name of its in-house therapy as EPPE, based on the active ingredient efpeglenatide. The drug is currently under review by Korea's Ministry of Food and Drug Safety (MFDS), with a launch targeted for the second half of this year.

If it clears approval, a "Made in Korea" drug will crash a market that two global giants have split between themselves. But this is far more than just another product launch, and here's why it matters.

💊 What Exactly Are These Drugs?

Wegovy, Mounjaro, and EPPE all share one root: they mimic a hormone called GLP-1.

GLP-1 is a hormone your gut naturally releases when you eat. It signals the brain that you're full and slows down how quickly food leaves the stomach, keeping you satisfied for longer. The catch is that this hormone disappears from the body within minutes. Drugmakers engineered injectable versions that copy the hormone but linger far longer in the body, and that is exactly what today's weight-loss injections are. The whole category is called "GLP-1 receptor agonists," which sounds technical but really just means a drug that presses your fullness switch for you.

Mounjaro takes it a step further. Unlike Wegovy, which targets GLP-1 alone, Mounjaro also stimulates a second metabolic hormone called GIP. Flipping two switches instead of one produces stronger weight loss, and this very difference is the key to the market upheaval we'll get to next.

📈 Why This News Blew Up Right Now

This isn't just patriotic hype about a "domestic drug." The real reason is that the market itself is in the middle of a violent shake-up.

Wegovy planted its flag first in Korea. But Mounjaro, arriving later, flipped the board almost overnight. According to IQVIA, the leading global tracker of drug prescriptions and sales, Mounjaro launched in Korea in August 2025 and posted 191.6 billion won in Q4 that year, overtaking Wegovy (123.4 billion won) for the first time. The gap widened in Q1 2026, with Mounjaro at 323.2 billion won versus Wegovy's 104 billion won, more than triple. Within just eight months, cumulative sales topped 540 billion won, and monthly prescriptions surpassed 200,000.

The same story played out globally. Mounjaro generated 8.7 billion dollars in Q1 2026, dethroning even the famed cancer drug Keytruda to become the world's top-selling medicine by quarterly revenue. Meanwhile, Novo Nordisk, the pioneer behind Wegovy, saw its growth stall and reshuffled its executive team in a scramble to defend its turf.

In short, the battlefield shifted from "who arrived first" to "who has the better product," and the Korean newcomer is entering at precisely that moment. Had the market been frozen solid, a new entrant would have been reckless. But right now there's a genuine opening, and that timing is what makes this news so significant.

🔬 So How Good Is EPPE, Really?

The question everyone cares about is how much weight actually comes off. Hanmi ran a Phase 3 trial (the final large-scale stage that verifies a drug's efficacy and safety in humans) with 448 Korean adults with obesity. Interim results at week 40 showed an average weight loss of 9.75 percent, a clear contrast with the placebo group, which lost just 0.95 percent. About 79 percent of participants lost at least 5 percent of their body weight, and nearly half, 49 percent, lost more than 10 percent.

To be candid, those numbers fall short of Mounjaro (around 20 percent in trials) and Wegovy (roughly 13 percent). Many will ask, "Then why bother?" And this is exactly the point most people miss. EPPE was never chasing the top spot on the scale.

🧩 The Real Battleground Nobody Asks About

Isn't the drug that sheds the most weight the automatic winner? On the ground, the logic is different.

First is side-effect management. The most common side effects of GLP-1 drugs are nausea, vomiting, and diarrhea. Because the drug works by slowing the stomach, digestive discomfort is baked in, and a surprising number of patients quit mid-treatment because they can't tolerate it. Hanmi built in its proprietary LAPSCOVERY technology, a long-acting platform designed to release the drug gradually rather than all at once. Think of it as turning a roller coaster of spiking-and-crashing drug levels into a gentle hill. This reduces the stomach-churning side effects and eases the injection burden. The bet is that keeping patients on the drug matters more in real-world prescribing than squeezing out a few extra percentage points of weight loss.

Second is price and supply, and this may be EPPE's true weapon. Most weight-loss drugs in Korea are non-reimbursed, meaning national health insurance covers nothing and patients pay the full cost, often hundreds of thousands of won a month. On top of that, Wegovy and Mounjaro are made overseas and imported, so shortages have been recurring. EPPE, by contrast, is manufactured directly at Hanmi's Pyeongtaek Smart Plant, an automated, state-of-the-art facility. Domestic production means stable supply, and cutting out import margins and logistics costs leaves plenty of room to lower the price. Even if it lags slightly on weight loss, a drug that's clearly cheaper every month and never out of stock could shift consumer choices.

Third is the weight of the data. EPPE was originally developed as a diabetes drug, and along the way it completed a cardiovascular outcomes trial (CVOT) involving roughly 4,000 people, a large, long-term study checking whether a drug harms the heart and blood vessels over time. Since weight-loss drugs are taken long-term even by otherwise healthy people, long-term safety is paramount, and EPPE already has a thick file of evidence here. The fact that its trial was conducted in Korean patients rather than Westerners also carries real persuasive power in domestic clinics.

🏇 A Three-Way Race Already Underway, With More Behind

A lineup of Korean players is queuing up behind EPPE. HK inno.N is running Phase 3 trials with ecnoglutide, licensed from China, which showed up to 15.1 percent weight loss in global studies. JW Pharmaceutical brought in bofanglutide, dosed just once every two weeks, easing the burden versus weekly shots. Daewoong Pharmaceutical is developing a microneedle patch (tiny drug-coated needles that dissolve into the skin to deliver medicine) instead of an injection, while Chong Kun Dang and Ildong are working on oral pill versions.

Here's an added insight: the competitive axis in this market is moving from "how much you lose" to "how, how long, and how comfortably you can use it." Early on, the weight-loss number was everything. Now the race is expanding to drugs that manage muscle loss (the problem where slimming down strips away precious muscle along with fat), drugs that erase needle anxiety through pills and patches, and drugs that tackle diabetes, heart disease, and fatty liver all at once. Hanmi, too, is separately developing a muscle-preserving candidate and a triple-agonist that hits three mechanisms simultaneously.

🔭 What Should Consumers Watch For?

Domestic doesn't automatically mean better, and a lower weight-loss figure doesn't make it a failure. Three things are worth watching. How cheaply the launch price is set versus Wegovy and Mounjaro, how low the real-world dropout rate from stomach side effects turns out to be, and whether it eventually makes it onto the national insurance reimbursement list. That last point is the variable that could shake the entire market. Right now the high out-of-pocket cost keeps the barrier to entry high, so if a domestic drug leverages its price edge to enter the reimbursed tier first, the landscape could be redrawn overnight.

Ultimately, EPPE's arrival isn't a story about how well it caught up to foreign drugs. It's a story about whether it can rewrite the market's long-frozen rules. The real starting gun will fire the moment approval and the actual launch price are revealed later this year.

One final note: weight-loss injections are prescription-only medicines that must be used under a doctor's diagnosis and supervision. Whether any drug suits you depends on your health status and underlying conditions, so please consult a physician before starting treatment.